adat2 Antibody

What is ADAT2 and what is its role in tRNA modification?

ADAT2 (adenosine deaminase tRNA specific 2) is a 191 amino acid protein (approximately 21 kDa) that belongs to the cytidine and deoxycytidylate deaminase family. It functions as part of the ADAT2/ADAT3 heterodimeric complex responsible for the deamination of adenosine-34 to inosine in many tRNAs. This modification is critical for proper tRNA function and translation fidelity . ADAT2 provides the catalytic activity within this complex, while ADAT3 serves as the catalytically inactive subunit that contributes to substrate recognition and complex stability . The enzyme is expressed in numerous tissues, including the appendix, urinary bladder, and adrenal gland, suggesting its fundamental role in cellular processes across different cell types .

What are the primary applications for ADAT2 antibodies in research?

ADAT2 antibodies are versatile tools employed in multiple molecular and cellular biology techniques:

These applications facilitate investigations into ADAT2 expression patterns, protein-protein interactions (particularly with ADAT3), and subcellular localization in various experimental models .

How should researchers choose between polyclonal and monoclonal ADAT2 antibodies?

The choice between polyclonal and monoclonal ADAT2 antibodies depends on the research objectives:

Polyclonal antibodies (such as 13621-1-AP) offer:

• Recognition of multiple epitopes, providing strong signal amplification

• Greater tolerance to minor protein denaturation or conformational changes

• Broader cross-reactivity across species (human, mouse, rat)

• Particularly useful for initial characterization studies and applications requiring high sensitivity

Monoclonal antibodies provide:

• Consistent lot-to-lot reproducibility

• Higher specificity for a single epitope

• Reduced background in some applications

• Preferable for quantitative analyses and comparative studies

For co-immunoprecipitation studies investigating ADAT2/ADAT3 interactions, antibodies with minimal cross-reactivity between these proteins are essential, as demonstrated in previous research using recombinant ADAT2, ADAT3, and TRM140 antibodies .

What controls should be included when validating ADAT2 antibody specificity?

Proper validation of ADAT2 antibodies requires rigorous controls:

• Positive tissue/cell controls: Mouse brain tissue, mouse pancreas tissue, and A431 cells have been validated for ADAT2 expression and should be considered as positive controls .

• Knockdown/knockout validation: Implementing ADAT2-targeted miRNAs can achieve approximately 83% reduction in protein levels, providing an excellent negative control. Such approaches have been used to confirm antibody specificity and to study ADAT2 function in neuronal migration .

• Peptide competition assays: Pre-incubation of the antibody with the immunizing peptide should abolish specific signals.

• Cross-reactivity assessment: Testing against recombinant ADAT2 and related proteins (ADAT3, TRM140) to ensure minimal cross-reactivity, particularly important for co-immunoprecipitation experiments .

• Multiple antibody approach: Using antibodies targeting different epitopes of ADAT2 to confirm consistent localization and expression patterns.

How can researchers optimize co-immunoprecipitation protocols for studying ADAT2/ADAT3 complexes?

Optimizing co-immunoprecipitation of ADAT2/ADAT3 complexes requires attention to several factors:

• Antibody selection: Use antibodies with demonstrated specificity for either ADAT2 or ADAT3 that have negligible cross-reactivity. Previous studies have successfully employed reciprocal co-IP approaches using anti-ADAT2 and anti-TRM140a antibodies to demonstrate complex formation .

• Buffer composition: A suitable lysis buffer containing 200 mM KCl and 20 mM HEPES (pH 7.9) has been effective for maintaining complex integrity during extraction .

• Cross-linking considerations: For transient or weak interactions, mild cross-linking may stabilize the complex.

• Washing stringency: Balance between removing non-specific binding and preserving true interactions; typically, multiple washes with decreasing salt concentrations.

• Detection strategy: For simultaneous detection of both proteins, consider using antibodies raised in different species to avoid detection issues in the immunoblotting phase.

Research has shown that recombinant ADAT2/ADAT3 can be efficiently co-immunoprecipitated with TRM140a, indicating potential multi-protein complexes that may be relevant to the regulation of tRNA modification .

What methodological approaches are recommended for studying ADAT2's role in tRNA modification?

To investigate ADAT2's function in tRNA modification, researchers should consider:

• In vitro deamination assays: Using purified ADAT2/ADAT3 complex with synthetic or in vitro transcribed tRNA substrates to measure adenosine-to-inosine conversion.

• Microscale thermophoresis (MST): This technique has been successfully employed to study the binding affinity of mouse ADAT2/ADAT3 complex to various tRNA substrates including tRNA Val(AAC), tRNA Arg(ACG), tRNA Ala(AGC), and tRNA Gly(CCC), providing insights into substrate specificity .

• Mutagenesis analysis: The introduction of specific mutations in ADAT2 to identify critical residues for catalytic activity or complex formation with ADAT3. The structure of mouse ADAT2/ADAT3 complex provides a valuable reference for designing such mutations .

• tRNA sequencing: To monitor global changes in tRNA modification profiles upon ADAT2 manipulation (knockdown, knockout, or overexpression).

• Complementation assays: Testing the ability of wild-type or mutant ADAT2 to rescue phenotypes in ADAT2-deficient systems.

What are common issues when using ADAT2 antibodies in Western blot applications?

Researchers may encounter several challenges when using ADAT2 antibodies for Western blotting:

• Non-specific bands: ADAT2 has a predicted molecular weight of 21 kDa but is often observed at approximately 25 kDa on Western blots . This discrepancy should be noted when interpreting results. Additional bands may represent:

  • Post-translational modifications

  • Alternatively spliced isoforms (up to 2 different isoforms have been reported)

  • Non-specific binding

• Weak signal detection: Optimize protein extraction conditions to ensure efficient release of ADAT2, particularly from nuclear fractions where a portion of the enzyme can be found .

• Sample preparation considerations: Avoid repeated freeze-thaw cycles of samples, which may lead to protein degradation and inconsistent results.

• Antibody dilution optimization: Starting with the recommended dilution (1:500-1:1000 for Western blot), researchers should perform titration experiments to determine optimal concentration for their specific sample type .

• Blocking conditions: BSA-based blocking solutions may be preferable to milk for phosphorylation-sensitive epitopes.

How can researchers address challenges in detecting ADAT2 in tissue sections by immunohistochemistry?

When performing immunohistochemistry with ADAT2 antibodies, consider the following optimization strategies:

• Antigen retrieval methods: For optimal results with ADAT2 antibodies, TE buffer pH 9.0 is recommended for antigen retrieval, though citrate buffer pH 6.0 may be used as an alternative .

• Tissue-specific considerations: Human hepatocirrhosis tissue and human colon cancer tissue have been validated for ADAT2 antibody staining . When working with other tissue types, optimization may be required.

• Signal amplification: For tissues with low ADAT2 expression, consider using biotin-streptavidin or tyramide signal amplification systems.

• Background reduction: If high background is observed, increase washing steps, optimize blocking conditions, or consider using monoclonal antibodies for greater specificity.

• Dual staining approaches: When investigating ADAT2 localization in relation to ADAT3, sequential staining protocols with appropriate controls for cross-reactivity are essential.

How are ADAT2 antibodies used to investigate neurodevelopmental processes?

ADAT2 antibodies have become instrumental in studying neurodevelopmental processes:

• Neuronal migration studies: ADAT2 antibodies have been used to validate knockdown efficiency in experiments investigating the role of the ADAT2/ADAT3 complex in neuronal migration. Research has shown that depletion of ADAT2 (verified by both qPCR and immunoblotting) leads to migration defects comparable to those observed after ADAT3 silencing, with approximately 21% reduction in cells reaching the upper cortical plate .

• Subcellular localization analysis: Immunofluorescence studies using ADAT2 antibodies have helped reveal the subcellular distribution of this protein within neurons, contributing to our understanding of its function in neural cells.

• Protein-protein interaction mapping: Co-immunoprecipitation with ADAT2 antibodies enables the identification of neuron-specific interaction partners that may regulate its function during brain development.

• Expression profiling: Western blot analysis using ADAT2 antibodies allows researchers to track developmental changes in ADAT2 expression across different brain regions and developmental stages.

What insights have ADAT2 antibodies provided regarding the ADAT2/ADAT3 complex in disease models?

ADAT2 antibodies have contributed significantly to our understanding of disease mechanisms involving the ADAT2/ADAT3 complex:

• Neurodevelopmental disorders: Mutations in ADAT3, the catalytically inactive subunit of the ADAT2/ADAT3 complex, have been identified in patients with severe neurodevelopmental disorders. ADAT2 antibodies have been crucial in investigating how these mutations affect complex formation and stability .

• Protein level analysis in patient samples: Studies have used multiple ADAT2/ADAT3 antibodies to demonstrate that certain ADAT3 mutations (p.V144M/p.Y152H and p.A196V/p.A196L) result in reduced ADAT3 protein levels despite stable transcript levels, providing insights into disease mechanisms .

• Mutagenesis models: ADAT2 antibodies have helped validate experimental models studying the mutagenic potential of deaminase activity. Specifically, expression of ADAT2/ADAT3 or ADAT2 alone in E. coli leads to accumulation of rifampicin-resistant colonies, while co-expression with TRM140a reduces mutagenesis to background levels .

• Functional complementation studies: Antibodies have been used to confirm expression of ADAT2 in rescue experiments, where researchers test whether the catalytic activity of the ADAT2/ADAT3 complex is required for proper neuronal migration .

How can structural studies of the ADAT2/ADAT3 complex inform antibody selection and experimental design?

Recent structural studies of the mouse ADAT2/ADAT3 complex provide valuable insights for antibody-based research:

• Epitope accessibility: The solved structure of the ADAT2/ADAT3 complex reveals which regions of ADAT2 are surface-exposed versus buried in the complex, informing antibody selection for different applications. Antibodies targeting buried epitopes may be useful for detecting free ADAT2 but not the assembled complex .

• Conformational considerations: The structure indicates potential conformational changes that ADAT2 may undergo upon binding to ADAT3, which could affect epitope recognition by certain antibodies .

• Functional domain targeting: Antibodies directed against the catalytic domain of ADAT2 versus its interaction surfaces with ADAT3 can be strategically employed depending on the research question.

• Cross-species applications: Understanding structural conservation across species allows researchers to better predict cross-reactivity of ADAT2 antibodies between human, mouse, and other experimental models .

• Binding site analysis: The structure reveals how the ADAT2/ADAT3 complex recognizes tRNA substrates, providing context for interpreting experimental results when studying the impact of ADAT2 manipulation on tRNA modification .

What methodological advances are improving the specificity and utility of ADAT2 antibodies in research?

Recent technological advances have enhanced ADAT2 antibody applications:

• Recombinant antibody technology: Creation of recombinant ADAT2 antibodies with precisely defined epitopes and minimal batch-to-batch variation improves experimental reproducibility.

• Proximity ligation assays: These techniques allow visualization of ADAT2/ADAT3 interactions in situ, providing spatial information about complex formation within cells.

• CRISPR-validated antibodies: Some manufacturers now offer ADAT2 antibodies validated using CRISPR-Cas9 knockout cells, ensuring superior specificity.

• Single-domain antibodies: These smaller antibody formats may access epitopes that are sterically hindered in the ADAT2/ADAT3 complex and provide advantages for certain applications.

• Phospho-specific antibodies: As regulatory phosphorylation sites on ADAT2 are identified, phospho-specific antibodies will enable studies of post-translational regulation of ADAT2 function.